FendX Discusses Recent CDC Report on the Rise of Six Superbug Infections in the US

CDC reports burden of six hard-to-treat superbugs increased by a combined 20% in 2021 and 2022 compared with 2019

CDC call to action for more effective infection prevention and control, and the need for innovative prevention strategies

FendX’s goal is to develop innovative solutions using their nanotechnology that will contribute to reducing the spread of superbugs

Oakville, Ontario–(Newsfile Corp. – July 30, 2024) – FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX“), a nanotechnology company developing surface protection coatings to reduce the spread of pathogens, highlights a new report from the Centre of Disease Control (“CDC”) published on July 16, 2024 highlighting the increased incidence of infections caused by six antibiotic-resistant bacteria (commonly know as ‘superbugs’) and emphasized the need to invest in the prevention-focused public health initiatives that can effectively control their spread.

The new CDC report highlighted a combined 20% increase in infection rate from six difficult to treat superbugs in 2021 and 2022 compared to 2019. The CDC claims the rise in infection rates is likely due, in part, to the impact of COVID-19, which placed a significant strain on the healthcare system and employees, longer hospital stays and overuse of antibiotics.

Dr. Carolyn Myers, CEO and President of FendX states, “This CDC report reinforces the difficulty of controlling infections rates caused by superbugs and that a focus on infection control and new innovations is needed. At FendX, we are dedicated to developing innovative high-touch surface protection product solutions to reduce the spread of superbugs.” Dr. Myers continues, “Our goal is to actively contribute to the fight against superbug transmission and make peoples lives safer.”

About FendX Technologies Inc.

FendX is a Canada-based nanotechnology company focused on developing products to make people’s lives safer by reducing the spread of pathogens. The Company is developing both film and spray products to protect surfaces from contamination. The lead product under development, REPELWRAP™ film, is a protective surface coating film that, due to its repelling properties, prevents the adhesion of pathogens and reduces their transmission on surfaces prone to contamination. The spray nanotechnology is a bifunctional spray coating being developed to reduce contamination on surfaces by repelling and killing pathogens. The Company is conducting research and development activities using its nanotechnology in collaboration with industry-leading partners, including McMaster University. The Company has exclusive worldwide licenses to its technology and IP portfolio from McMaster, which encompass both film and spray coating nanotechnology formulations.

ON BEHALF OF FENDX TECHNOLOGIES INC.

“Carolyn Myers”
Carolyn Myers
Chief Executive Officer and Director

For more information, please visit https://fendxtech.com and the Company’s profile on SEDAR+ at www.sedarplus.ca.

Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release

Forward-Looking Statements

This news release contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; the Company’s goal of developing innovative high-touch surface protection product solutions to reduce the spread of superbugs and make peoples lives safer; the Company’s plans to develop new technologies to reduce the spread of pathogens; and products under development and any pathogen reduction benefits related thereto. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “aims,” “potential,” “goal,” “objective,” “prospective,” and similar expressions, or that events or conditions “will,” “would,” “may,” “can,” “could” or “should” occur, or are those statements, which, by their nature, refer to future events. The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and involve several risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and that actual results and future events could differ materially from those anticipated in such statements.

Important factors that could cause future results to differ materially from those anticipated in these forward-looking statements include: product candidates only being in formulation/reformulation stages; limited operating history; research and development activities; dependence on collaborative partners, licensors and others; effect of general economic and political conditions; and other risk factors set forth in the Company’s public filings which are available on SEDAR+ at www.sedarplus.ca. Accordingly, the reader is urged to refer to the Company’s such filings for a more complete discussion of such risk factors and their potential effects. Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors should change.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/218132